SIRT1 Regulates N6‐Methyladenosine RNA Modification in Hepatocarcinogenesis by Inducing RANBP2‐Dependent FTO SUMOylation
Autor: | Ruhong Li, Yanhong Zhou, Wei Xiong, Jianda Zhou, Fen Wang, Xiaohui Li, Fei Guo, Xiaoming Liu, Jianye Liu, Yuxing Zhu, Xiaoyan Wang, Ming Zhou, Qinghai Zeng, Qiang Wang, Xiaowei Xing, Ke Cao, Wen Xiao, Canxia Xu, Lian Gong, Hao Bo, Xiong Chen, Dong He |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Regulation of gene expression endocrine system diseases Hepatology biology Chemistry SUMO protein nutritional and metabolic diseases medicine.disease_cause GNAO1 Ubiquitin ligase 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Downregulation and upregulation biology.protein Cancer research medicine Demethylase 030211 gastroenterology & hepatology RANBP2 Carcinogenesis |
Zdroj: | Hepatology. 72:2029-2050 |
ISSN: | 1527-3350 0270-9139 |
Popis: | Background and aims Hepatocellular carcinoma (HCC) is associated with high malignancy rates. Recently, a known deacetylase silent information regulator 1 (SIRT1) was discovered in HCC, and its presence is positively correlated with malignancy and metastasis. N6 -methyladenosine (m6 A) is the most prominent modification, but the exact mechanisms on how SIRT1 regulates m6 A modification to induce hepatocarcinogenesis remain unclear. Approach and results Here we demonstrate that SIRT1 exerts an oncogenic role by down-regulating fat mass and obesity-associated protein (FTO), which is an m6 A demethylase. A crucial component of small ubiquitin-related modifiers (SUMOs) E3 ligase, RANBP2, is activated by SIRT1, and it is indispensable for FTO SUMOylation at Lysine (K)-216 site that promotes FTO degradation. Moreover, Guanine nucleotide-binding protein G (o) subunit alpha (GNAO1) is identified as m6 A downstream targets of FTO and tumor suppressor in HCC, and depletion of FTO by SIRT1 improves m6 A+ GNAO1 and down-regulates its mRNA expression. Conclusions We demonstrate an important mechanism whereby SIRT1 destabilizes FTO, steering the m6 A+ of downstream molecules and subsequent mRNA expression in HCC tumorigenesis. Our findings uncover a target of SIRT1 for therapeutic agents to treat HCC. |
Databáze: | OpenAIRE |
Externí odkaz: |